General Clinical Chemistry Analyzers and Accessories
Abcam Ispinesib (SB-715992), 50MG
MW 517.1 Da, Purity >98%. A potent, selective and reversible allosteric inhibitor of KSP with IC₅₀ value of 0.5 nM. Often combines with chemotherapy drugs to tumor treatment.
The product is subject to the following: Abcam Restricted Use Statement
Abcam LCL161, 5MG
MW 500.6 Da, Purity >99%. Small molecule SMAC mimetic inhibitor of multiple IAP (Inhibitor of apoptosis) family proteins. (IC₅₀ = 10.23 μM). Inhibits cell proliferation and viability in two human hepatocellular carcinoma cells (Hep3B, IC₅₀ = 10, and PLC5, IC₅₀ = 19).
The product is subject to the following: Abcam Restricted Use Statement
Abcam SGI1776, 5MG
MW 405.4 Da, Purity >99%. Novel ATP competitive inhibitor of Pim1 with IC50 of 7 nM, 50- and 10-fold selective versus Pim2 and Pim3. Preliminary results from studies treating prostate cancer cells.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Ispinesib (SB-715992), 5MG
MW 517.1 Da, Purity >98%. A potent, selective and reversible allosteric inhibitor of KSP with IC₅₀ value of 0.5 nM. Often combines with chemotherapy drugs to tumor treatment.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Binimetinib, MEK1/2 inhibitor, 25MG
MW 441.2 Da, Purity >99%. Potent and selective allosteric inhibitor of MEK1/2. Orally bioavailable. Achieve your results faster with highly validated, pure and trusted compounds.
The product is subject to the following: Abcam Restricted Use Statement
Abcam FC 131, C x CR4 activation inhibitor, 10MG
MW 729.8 Da, Purity >95%. FC 131, CXCR4 activation inhibitor. Achieve your results faster with highly validated, pure and trusted compounds.
The product is subject to the following: Abcam Restricted Use Statement
Abcam BAY-299, TAF1 and BRD1 inhibitor, 1MG
MW 429.5 Da, Purity >98%. Potent and selective bromodomain inhibitor of TAF1 (IC₅₀ = 8-13 nM) and BRD1 (IC₅₀ = 6-67 nM). More than 30-fold selective versus BRD9 and ATAD2. More than 300-fold selective versus BRD4. Inhibits BRD1 (IC₅₀ = 0.58 μM) and TAF1 (IC₅₀ = 0.9 μM) binding to Histone H4 in cell-based assays; also inhibits BRD1 (IC₅₀ = 0.83 μM) and TAF1 (IC₅₀ = 1.4 μM) binding to Histone H3.3.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Elvitegravir, quinolone HIV integrase inhibitor, 5MG
MW 447.9 Da, Purity >99%. Elvitegravir is an inhibitor of HIV integrase. It inhibits HIV integrase from HIV 1 IIIB (IC₅₀ = 0.7 nM), HIV 2 EHO (IC₅₀ = 2.8 nM) and HIV-2 ROD (IC₅₀ = 1.1 nM) in cell free assays. Elvitegravir blocks integration of HIV cDNA via inhibition of DNA strand transfer. Active against a range of HIV sub-types and against mulit-drug resistant clinical isolates. Potent (IC₅₀ range = 0.21 - 1.15 nM) HIV antiviral activity in various cell-based assays.
The product is subject to the following: Abcam Restricted Use Statement
Abcam FC 131, C x CR4 activation inhibitor, 1MG
MW 729.8 Da, Purity >95%. FC 131, CXCR4 activation inhibitor. Achieve your results faster with highly validated, pure and trusted compounds.
The product is subject to the following: Abcam Restricted Use Statement
Abcam V x -745, p38 alpha MAPK inhibitor, 1MG
MW 436.3 Da. Potent, selective p38 alpha MAPK inhibitor (IC₅₀ = 10 nM), with 20-fold selectivity over p38 beta and 1000-fold selectivity over closely related kinases, ERK1 and JNK1-3.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Dabrafenib, mutant B-Raf V600E inhibitor, 5MG
MW 519.6 Da, Purity >98%. Potent, ATP-competitive mutant B-Raf V600E inhibitor (IC50 = 0.7 nM), with selectivity versus wild-type B-Raf (IC50 = 5.2 nM) and c-RAf (IC50 = 6.3 nM) in cell-free assays. Antitumor activity *in vivo* in mouse models of B-Raf V600E melanoma.
The product is subject to the following: Abcam Restricted Use Statement
Abcam LY2874455, FGF/FGFR inhibitor, 25MG
MW 444.3 Da, Purity >98%. Potent FGF/FGFR inhibitor. Inhibits in vitro autophosphorylation of FGFR-1, FGFR-2, FGFR-3, and FGFR-4 with similar inhibition potency for all four FGFRs (IC₅₀ < 6.4 nM). Exhibits a 6- to 9-fold in vitro and in vivo selectivity on inhibition of FGF- over VEGF-mediated target signaling in mice.
The product is subject to the following: Abcam Restricted Use Statement
Abcam SB742457 (Intepirdine), 5-HT6 antagonist, 5MG
MW 353.4 Da. Potent (pKi = 9.63) and highly selective 5-HT6 antagonist. Greater thsan 100-fold selective against other receptors. Reverses learning impairment in animal models.
The product is subject to the following: Abcam Restricted Use Statement
Abcam LRRK2-IN-1, LRRK2 inhibitor, 10MG
MW 570.7 Da. Potent and selective inhibitor of the Parkinson's disease kinase LRRK2. Benzodiazepine based derivative. Inhibits both G2019S mutant and wild-type LRRK2 kinase activity (IC₅₀ values are 6 and 13 nM respectively). Causes dephosphorylation, ubiquitination and degradation of LRRK2. Inhibits IFN-γ-induced monocyte maturation in vitro.
The product is subject to the following: Abcam Restricted Use Statement
THERMO SCI 3P AIG PARTS & ACCESSORIES TIN DISKS 30 MM SET OF 100
50-134-6835 TIN DISKS 30 MM SET OF 100
